ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2106

Features of Pneumocystis Jirovecii Pneumonia in Juvenile Idiopathic Inflammatory Myopathy

Sara Sabbagh1, Jessica Neely 2, Jamie Lai 3, Anjali Sura 4, Kelly Rouster-Stevens 5, Svetlana Lvovich 6, Tara McGrath 7, Lori Tucker 8, Heinrike Schmeling 9, Jordan Roberts 10, Lisa G. Rider 11 and Susan Kim 2, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, 2University of California, San Francisco, San Francisco, CA, 3Department of Pediatrics, University of Colorado School of Medicine, Division of Pediatric Rheumatology, Children’s Hospital Colorado, Aurora, CO, 4University of Michigan, Ann Arbor, MI, 5Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, 6Section of Rheumatology, Department of Pediatrics, St. Christopher's Hospital for Children, Drexel University College of Medicine, Philadelphia, PA, 7Division of Rheumatology, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada, 8British Columbia Children’s Hospital, Vancouver, Canada, 9Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 10Boston Children’s Hospital, Harvard Medical School, Boston, MD, 11Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Bethesda, MD

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: juvenile dermatomyositis, pneumocystis and opportunistic infections

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Infection-Related Rheumatic Disease Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Approximately 6% of adults with idiopathic inflammatory myopathy (IIM) develop Pneumocystis jirovecii pneumonia (PJP), and PJP confers higher mortality in IIM patients compared to other connective tissue diseases. There are few studies examining PJP in juvenile IIM (JIIM). Our purpose was to characterize the clinical features associated with PJP infections in JIIM.

Methods: An electronic REDCap survey of 215 questions regarding JIIM disease course, medication usage, and PJP infection was sent to members of the Pediatric Rheumatology Bulletin Board, an electronic list-serv, and members of the Childhood Arthritis and Rheumatology Research Alliance. Retrospective chart review of JIIM patients who developed PJP was completed by the primary treating physician.

Results: Survey data were completed for nine juvenile dermatomyositis and one juvenile polymyositis patients who developed PJP infection between ages 1.7-18 years. Of these, 6/10 were male and the median age of IIM disease onset was 5.9 years (range 1.6-17.2 years).  At IIM disease onset, 9/10 had weakness, 8/10 had Gottron’s papules or heliotrope rash, 6/10 had dysphonia, and 5/10 had skin ulcers. Myositis specific autoantibodies (MSA) were obtained in 9 patients: 4 were positive for anti-MDA5, 1 was positive for anti-p155/140, and 4 were MSA negative. Anti-Ro (SSA) autoantibodies were present in 5/9 patients. The median duration from IIM onset to PJP diagnosis was 3.7 months (IQR 1.7-6.9 months). At PJP diagnosis, IIM disease severity was moderate in 7/10 and severe in 2/10 patients. At the time of PJP infection, 2 patients had interstitial lung disease, one of whom also had pulmonary hypertension. The average white blood cell count at PJP diagnosis was 12.7 thousand cells/µl and 3/10 patients had a low absolute lymphocyte count (range 76-590 cells/µl). Symptoms at PJP presentation included dyspnea on exertion (10/10), hypoxia (9/10), fever (8/10), cough (8/10), and tachycardia (8/10). Mean time from symptom onset to initiation of treatment for PJP was 1 week. The average daily dose of oral prednisone was 30mg (1.1 mg/kg/day) with 8/10 patients on ≥20mg prednisone daily, and 7/10 receiving IV pulse steroids the month prior. Only 2 patients received cyclophosphamide and/or rituximab prior to PJP. Eight patients required ICU admission and 6/10 required mechanical ventilation for an average of 49 days. Two patients required extracorporeal membrane oxygenation, both of whom died secondary to complications of PJP infection. None of the patients had received PJP prophylaxis prior to infection.

Conclusion: PJP affects JIIM patients receiving systemic immunosuppression.  Most patients with PJP had moderate to severe disease at diagnosis. Skin ulcerations and anti-MDA5 autoantibodies were commonly reported.  Infection with PJP occurred in the first 6 months of disease in the majority of patients, and most patients were receiving high doses of prednisone (≥20 mg) and IV pulse steroids.  Due to the high mortality associated with PJP, prophylaxis may be warranted in a subset of JIIM patients with these disease features, especially early in the disease course when higher doses of steroids are required to control disease.


Disclosure: S. Sabbagh, None; J. Neely, None; J. Lai, None; A. Sura, None; K. Rouster-Stevens, None; S. Lvovich, None; T. McGrath, None; L. Tucker, None; H. Schmeling, F. Hoffmann-La Roche Ltd, 2, Janssen, 2, Pfizer, 2, UCB Biosciences GmbH, 2; J. Roberts, None; L. Rider, ., 2, 9, aTyr, 9, Bristol Myers Squibb, 2, Cure JM Foundation, 2, 9, Eli Lilly and Company, 9, Hope Pharmaceuticals, 2, Lilly-drug, 9, MedImmune / AstraZeneca, 9, MedImmune/AstraZeneca, 9, NIEHS, 2, NIEHS, NIH, 2, NIH, 2; S. Kim, None.

To cite this abstract in AMA style:

Sabbagh S, Neely J, Lai J, Sura A, Rouster-Stevens K, Lvovich S, McGrath T, Tucker L, Schmeling H, Roberts J, Rider L, Kim S. Features of Pneumocystis Jirovecii Pneumonia in Juvenile Idiopathic Inflammatory Myopathy [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/features-of-pneumocystis-jirovecii-pneumonia-in-juvenile-idiopathic-inflammatory-myopathy/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/features-of-pneumocystis-jirovecii-pneumonia-in-juvenile-idiopathic-inflammatory-myopathy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology